Weekly roundup highlights Biohaven’s challenge to Eli Lilly and industry competition with China
read at Endpoints ↗DealNeutral
The latest Endpoints Weekly issue focuses on a series of recent deals across the biotech sector, offering readers a snapshot of market activity.
Among the items highlighted is Biohaven’s strategic move to compete directly with Eli Lilly, signaling heightened rivalry in their therapeutic areas.
The issue also touches on broader industry concerns about competition from Chinese firms, underscoring the geopolitical pressures shaping biotech strategies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Deals, deals, deals; Biohaven takes on Eli Lilly; and more”
read at Endpoints ↗82 words · retrieved Jul 11
comments(0)
5-min edit window · permanent after that